Stability of cidofovir in extemporaneously prepared syringes

American Journal of Health-System Pharmacy

Volumn 62, Issue 5, 2005, Pages 506-509

  Hennere, Gaëlle ^a   Havard, Laurent ^a   Bonan, Brigitte ^a   Prognon, Patrice ^a,b,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b Department of Economic and Social Sciences   (France)

^c GPEH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR;

ARTICLE; DRUG DEGRADATION; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OSMOLALITY; PH MEASUREMENT; PRIORITY JOURNAL; SYRINGE;

EID: 14744294554     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.5.506     Document Type: Article

References (14)

1. Lea AP, Bryson HM. Cidofovir. Drugs. 1996; 52:225-31.
2. Chhetri DK, Blumin JH, Shapiro NL et al. Office-based treatment of laryngeal papillomatosis with percutaneous injection of cidofovir. Otolaryngol Head Neck Surg. 2002; 126:642-8.
3. Bielamowicz S, Villagomez V, Stager SV et al. Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope. 2002; 112:696-9.
4. El Aatmani M. [Translated title.] J Pharm Clin. 2002; 21:287-90. In French.
5. Snoeck R, Wellens W, Desloovere C et al. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir ((S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine). J Med Virol. 1998; 54:219-25.
6. Van Cutsem E, Snoeck R, Van Ranst M et al. Successful treatment of a squamous papilloma of the hypopharynxesophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J Med Virol. 1995; 45:230-5.
7. Pransky SM, Magit AE, Kearns DB et al. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg. 1999; 125:1143-8.
8. Dancey DR, Chamberlain DW, Krajden M et al. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature. Chest. 2000; 118:1210-4.
9. Chen T, Weston KE, Nassar MN et al. Kinetics of degradation of S(-)-1-(3-hydroxy-2-phosphonylmethoxy-1-propyl) cytosine (BMY-41671) in aqueous solution. Pharm Res. 1991; 8S:100.
10. Yuan LC, Samuels GJ, Visor GC. Stability of cidofovir in 0.9% sodium chloride injection and in 5% dextrose injection. Am J Health-Syst Pharm. 1996; 53:1939-43.
11. Ennis RD, Dahl TC. Stability of cidofovir in 0.9% sodium chloride injection for five days. Am J Health-Syst Pharm. 1997; 54:2204-6.
12. Oliyai R, Lee WA, Visor GC et al. Enhanced chemical stability of the intracellular prodrug, 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl) methyl] cytosine, relative to its parent compound, cidofovir. Int J Pharm. 1999; 179:257-65.
13. ICH harmonised tripartite guideline. Validation of analytical procedures: methodology. Fed Regist. 1997; 62:27463-7.
14. General test chapter 621. In: The United States pharmacopeia, 27th ed., and the national formulary 22nd ed. Rockville, MD: United States Pharmacopeial Convention; 2004.